Developer docs
API playgroundTry for free, no card

Search company profiles

Allos Therapeutics

Full company profile

uuid0009dn4

Namestring
Allos Therapeutics
Websiteurl
allos.com
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Allos Therapeutics operates a causal AI platform designed to improve pharmaceutical development by simulating how interventions affect outcomes before physical experiments are run. The platform functions as a closed-loop learning system that ingests structured data from every experimental run and deviation, providing pharmaceutical developers with a single source of truth featuring traceable drivers, documented assumptions, and controlled version history. The system is organized into four integrated modules spanning the molecule-to-process continuum: Formulation Development (phase-space mapping and simulation-led Design of Experiments), Scale-Up (validated operating windows with early risk signals), Tech Transfer and QA (inspection-aware, version-controlled decisions), and Clinical Trials (real-world data integration and patient stratification).

The company monetizes through enterprise SaaS subscriptions sold via a consultative direct sales motion targeting pharmaceutical companies, with quote-based pricing and 'Talk to a Process Expert' CTAs indicating a solution-selling approach requiring technical validation and regulatory compliance alignment. Reported customer outcomes include 50% lower inter-patient variability and 70% fewer scale-up and technology transfer failures, though these are company-reported without disclosed methodology. The platform emphasizes regulatory compliance and version-controlled decisions to support tech transfer and quality assurance in regulated pharma environments, and headcount is reported at 101-250 employees.

Firmographic inputs (biopharma, anti-cancer therapeutics, founded 1992, Berkeley HQ) and a 2002 funding round from Aisling Capital with Stephen J. Hoffman as Chairman appear to reference the legacy Allos Therapeutics biopharmaceutical company (later acquired by Spectrum Pharmaceuticals) rather than the current AI platform business operating at allos.ai. The current website is treated as the authoritative first-party source for the company's product, technology, and business model.

Short descriptiontext

Allos Therapeutics operates a causal AI platform for pharmaceutical development, simulating how interventions affect outcomes before physical experiments and learning from every run. Its closed-loop platform serves enterprise pharma developers across formulation, scale-up, tech transfer, QA, and clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
causal AI platform, pharmaceutical process development, formulation development software, design of experiments, scale-up tech transfer
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
AI-Driven Pharmaceutical Process Development Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AI Platform Subscription
TypeSubscription Recurring
Description

SaaS-based AI platform providing simulation and experimental design capabilities for pharmaceutical development. The platform appears to be sold as an enterprise software solution with licensing and subscription components, likely with professional services for implementation and validation.

allos.ai
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Allos Therapeutics sells a causal AI software platform that simulates how pharmaceutical interventions affect outcomes before physical experiments are run. The platform combines simulation-led Design of Experiments, phase-space mapping, validated operating windows, inspection-aware decision documentation, and patient stratification into a single closed-loop system covering formulation development, scale-up, tech transfer & QA, and clinical trials for pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 50% lower inter-patient variability
+1 more record
Product overview1 text field

Allos Therapeutics offers a single unified platform called 'The Allos Platform' — a causal AI solution for pharmaceutical development. The platform integrates four core modules: Formulation Development (phase-space mapping + simulation-led DoE), Scale-Up (validated operating windows + early risk signals), Tech Transfer & QA (inspection-aware, version-controlled decisions), and Clinical Trials (real world data, patient stratification). The platform is designed to work as one closed-loop system from molecule to validated process, with traceable drivers, documented assumptions, and controlled version history serving as the single source of truth.

Product and service1 record
1The Allos Platform
CategoryAI-Driven Pharmaceutical Process Development Software
Description

The Allos Platform is a causal AI software system for pharmaceutical development that simulates how interventions affect outcomes before physical experiments are run. It integrates Formulation Development (phase-space mapping and simulation-led DoE), Scale-Up (validated operating windows and early risk signals), Tech Transfer & QA (inspection-aware, version-controlled decisions), and Clinical Trials (real-world data integration and patient stratification) into a single closed-loop system with traceable drivers, documented assumptions, and controlled version history serving as a single source of truth. It is targeted at enterprise pharmaceutical and biotech companies seeking to reduce experiments, lower inter-patient variability, and minimize scale-up and tech-transfer failures.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Schrödinger provides computational chemistry and physics-based simulation software for pharma R&D, including formulation and process development. Most directly comparable to Allos in applying simulation-led methods to drug development workflows, with overlapping customer base in pharmaceutical companies.

TypeDirect peer
Description

Aitia applies causal AI specifically to pharmaceutical and biotech R&D, modeling causal relationships in biological systems to accelerate drug discovery and clinical development. Most architecturally comparable to Allos given the shared causal AI methodology and pharma R&D focus.

TypeDirect peer
Description

Insilico Medicine applies AI/ML across the drug discovery pipeline, from target identification through clinical development. Comparable to Allos as an AI platform serving pharma development workflows, though focused more upstream on discovery than formulation/scale-up.

TypeDirect peer
Description

Recursion uses AI-driven high-throughput experimentation to drive pharmaceutical R&D. Comparable to Allos in combining experimental data with AI for pharma development, though Recursion operates its own internal pipeline rather than primarily as a SaaS platform.

TypeDirect peer
Description

CytoReason applies AI-driven models of the immune system and disease biology to support pharma R&D and clinical development decisions. Comparable to Allos in serving pharma customers with AI-augmented development insights, including patient stratification and trial design.

TypeDirect peer
Description

InSilicoTrials provides simulation and digital-twin platforms for clinical trial design and pharmaceutical R&D. Comparable to Allos in applying simulation-led methodology to pharmaceutical development, including regulatory-grade validation pathways.

TypeDirect peer
Description

XtalPi combines AI, quantum physics, and robotics for drug discovery and formulation development. Comparable to Allos in using AI/simulation to optimize pharmaceutical development, particularly around formulation and crystallization workflows.

8Iambic Therapeutics
TypeEmerging player
Description

Iambic Therapeutics applies AI to drug discovery and design, including physics-informed models. Comparable to Allos as a next-generation AI platform targeting pharmaceutical development, though more discovery-focused than process/formulation-focused.

TypeBroad incumbent
Description

Dassault Systèmes' BIOVIA portfolio provides enterprise scientific software for pharmaceutical R&D, including formulation, scale-up, and quality management. Comparable to Allos as a broader pharma development platform with deeper enterprise install base and regulatory validation.

10Unlearn.AI
TypeEmerging player
Description

Unlearn applies AI to clinical trial design and patient stratification through prognostic digital twins. Comparable to Allos's clinical trial module in applying AI to optimize trial outcomes and patient selection in pharma development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Allos Therapeutics

AI-Driven Pharmaceutical Process Development Softwareallos.com

Allos Therapeutics operates a causal AI platform for pharmaceutical development, simulating how interventions affect outcomes before physical experiments and learning from every run. Its closed-loop platform serves enterprise pharma developers across formulation, scale-up, tech transfer, QA, and clinical trials.

What Allos Therapeutics does

Allos Therapeutics operates a causal AI platform designed to improve pharmaceutical development by simulating how interventions affect outcomes before physical experiments are run. The platform functions as a closed-loop learning system that ingests structured data from every experimental run and deviation, providing pharmaceutical developers with a single source of truth featuring traceable drivers, documented assumptions, and controlled version history. The system is organized into four integrated modules spanning the molecule-to-process continuum: Formulation Development (phase-space mapping and simulation-led Design of Experiments), Scale-Up (validated operating windows with early risk signals), Tech Transfer and QA (inspection-aware, version-controlled decisions), and Clinical Trials (real-world data integration and patient stratification).

The company monetizes through enterprise SaaS subscriptions sold via a consultative direct sales motion targeting pharmaceutical companies, with quote-based pricing and 'Talk to a Process Expert' CTAs indicating a solution-selling approach requiring technical validation and regulatory compliance alignment. Reported customer outcomes include 50% lower inter-patient variability and 70% fewer scale-up and technology transfer failures, though these are company-reported without disclosed methodology. The platform emphasizes regulatory compliance and version-controlled decisions to support tech transfer and quality assurance in regulated pharma environments, and headcount is reported at 101-250 employees.

Firmographic inputs (biopharma, anti-cancer therapeutics, founded 1992, Berkeley HQ) and a 2002 funding round from Aisling Capital with Stephen J. Hoffman as Chairman appear to reference the legacy Allos Therapeutics biopharmaceutical company (later acquired by Spectrum Pharmaceuticals) rather than the current AI platform business operating at allos.ai. The current website is treated as the authoritative first-party source for the company's product, technology, and business model.

Allos Therapeutics firmographics

Firmographics
Name
Allos Therapeutics
Website
https://allos.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
101–250 employees
Short description
Allos Therapeutics operates a causal AI platform for pharmaceutical development, simulating how interventions affect outcomes before physical experiments and learning from every run. Its closed-loop platform serves enterprise pharma developers across formulation, scale-up, tech transfer, QA, and clinical trials.
Ownership category
akta.pro rank

Allos Therapeutics industry classification

Industry
Product category
AI-Driven Pharmaceutical Process Development Software
NAICS
Computer Systems Design and Related Services (54151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Causal AI platform
  • Pharmaceutical process development
  • Formulation development software
  • Design of experiments
  • Scale-up tech transfer

Where Allos Therapeutics is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Markets served

Allos Therapeutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI Platform Subscription: SaaS-based AI platform providing simulation and experimental design capabilities for pharmaceutical development. The platform appears to be sold as an enterprise software solution with licensing and subscription components, likely with professional services for implementation and validation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Allos Therapeutics product offering

Product offering

Core offering

Allos Therapeutics sells a causal AI software platform that simulates how pharmaceutical interventions affect outcomes before physical experiments are run. The platform combines simulation-led Design of Experiments, phase-space mapping, validated operating windows, inspection-aware decision documentation, and patient stratification into a single closed-loop system covering formulation development, scale-up, tech transfer & QA, and clinical trials for pharmaceutical companies.

Product overview

Allos Therapeutics offers a single unified platform called 'The Allos Platform' — a causal AI solution for pharmaceutical development. The platform integrates four core modules: Formulation Development (phase-space mapping + simulation-led DoE), Scale-Up (validated operating windows + early risk signals), Tech Transfer & QA (inspection-aware, version-controlled decisions), and Clinical Trials (real world data, patient stratification). The platform is designed to work as one closed-loop system from molecule to validated process, with traceable drivers, documented assumptions, and controlled version history serving as the single source of truth.

Differentiator

Problem solved

Functional benefit

Products and services

  • The Allos Platform The Allos Platform is a causal AI software system for pharmaceutical development that simulates how interventions affect outcomes before physical experiments are run. It integrates Formulation Development (phase-space mapping and simulation-led DoE), Scale-Up (validated operating windows and early risk signals), Tech Transfer & QA (inspection-aware, version-controlled decisions), and Clinical Trials (real-world data integration and patient stratification) into a single closed-loop system with traceable drivers, documented assumptions, and controlled version history serving as a single source of truth. It is targeted at enterprise pharmaceutical and biotech companies seeking to reduce experiments, lower inter-patient variability, and minimize scale-up and tech-transfer failures.

Quantifiable outcome

  • 50% lower inter-patient variability
  • +1 more outcomes

Companies that use Allos Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Allos Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Allos Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Allos Therapeutics competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software for pharma R&D, including formulation and process development. Most directly comparable to Allos in applying simulation-led methods to drug development workflows, with overlapping customer base in pharmaceutical companies.
  • Aitia (formerly GNS Healthcare): Aitia applies causal AI specifically to pharmaceutical and biotech R&D, modeling causal relationships in biological systems to accelerate drug discovery and clinical development. Most architecturally comparable to Allos given the shared causal AI methodology and pharma R&D focus.
  • Insilico Medicine: Insilico Medicine applies AI/ML across the drug discovery pipeline, from target identification through clinical development. Comparable to Allos as an AI platform serving pharma development workflows, though focused more upstream on discovery than formulation/scale-up.
  • Recursion Pharmaceuticals: Recursion uses AI-driven high-throughput experimentation to drive pharmaceutical R&D. Comparable to Allos in combining experimental data with AI for pharma development, though Recursion operates its own internal pipeline rather than primarily as a SaaS platform.
  • CytoReason: CytoReason applies AI-driven models of the immune system and disease biology to support pharma R&D and clinical development decisions. Comparable to Allos in serving pharma customers with AI-augmented development insights, including patient stratification and trial design.
  • InSilicoTrials: InSilicoTrials provides simulation and digital-twin platforms for clinical trial design and pharmaceutical R&D. Comparable to Allos in applying simulation-led methodology to pharmaceutical development, including regulatory-grade validation pathways.
  • XtalPi: XtalPi combines AI, quantum physics, and robotics for drug discovery and formulation development. Comparable to Allos in using AI/simulation to optimize pharmaceutical development, particularly around formulation and crystallization workflows.

Emerging players

  • Iambic Therapeutics: Iambic Therapeutics applies AI to drug discovery and design, including physics-informed models. Comparable to Allos as a next-generation AI platform targeting pharmaceutical development, though more discovery-focused than process/formulation-focused.
  • Unlearn.AI: Unlearn applies AI to clinical trial design and patient stratification through prognostic digital twins. Comparable to Allos's clinical trial module in applying AI to optimize trial outcomes and patient selection in pharma development.

Broad incumbents

  • Dassault Systèmes (BIOVIA): Dassault Systèmes' BIOVIA portfolio provides enterprise scientific software for pharmaceutical R&D, including formulation, scale-up, and quality management. Comparable to Allos as a broader pharma development platform with deeper enterprise install base and regulatory validation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Allos Therapeutics social profiles

Digital presence

Allos Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Allos Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Allos Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Allos Therapeutics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allos Therapeutics

What does Allos Therapeutics do?

Allos Therapeutics sells a causal AI software platform that simulates how pharmaceutical interventions affect outcomes before physical experiments are run. The platform combines simulation-led Design of Experiments, phase-space mapping, validated operating windows, inspection-aware decision documentation, and patient stratification into a single closed-loop system covering formulation development, scale-up, tech transfer & QA, and clinical trials for pharmaceutical companies.

When was Allos Therapeutics founded?

Allos Therapeutics was founded in 1992. It employs 101 to 250 people.

Where is Allos Therapeutics based?

Allos Therapeutics is headquartered in Berkeley, United States, in the North America region.

How does Allos Therapeutics make money?

One revenue line is on record: AI Platform Subscription.

Who are Allos Therapeutics's main competitors?

Direct peers on record are Schrödinger, Aitia (formerly GNS Healthcare), Insilico Medicine, Recursion Pharmaceuticals, CytoReason, InSilicoTrials and XtalPi. Emerging players are Iambic Therapeutics and Unlearn.AI. Dassault Systèmes (BIOVIA) is listed as a broad incumbent.

Does Allos Therapeutics have an API?

No public API is recorded for Allos Therapeutics.

What industry is Allos Therapeutics in?

Allos Therapeutics's product category is AI-Driven Pharmaceutical Process Development Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54151 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals